Results 181 to 190 of about 64,689 (285)
ABSTRACT Objective Walking capacity declines prematurely in individuals with ataxia telangiectasia. However, granular data on walking capacity loss in ataxia telangiectasia are scarce. In this large cross‐sectional cohort, we describe age‐related walking capacity loss reported by participants and compare categories of a subjective walking capacity ...
Biljana Horn +6 more
wiley +1 more source
Australia versus Denmark: an analysis of foot-and-mouth disease mitigation strategies. [PDF]
Wagner A, Boklund AE, Ward MP.
europepmc +1 more source
Abstract Endogenous oxytocin plays an important role in lactation, but its effectiveness as an exogenous galactagogue has been modest due to dose‐limiting side effects related to off‐target effects at the vasopressin V2 receptor. Merotocin (FE 202767) is a short‐acting peptidic oxytocin receptor agonist with the potential to aid mothers experiencing ...
Yu Bagger +4 more
wiley +1 more source
Antigenic differences between strains of foot-and-mouth disease virus of type SAT 1 [PDF]
N. St. G. Hyslop +2 more
openalex +1 more source
Advancements in antiviral approaches against foot-and-mouth disease virus: a comprehensive review. [PDF]
Mohamadin M +5 more
europepmc +1 more source
Pss knockdown in the midgut causes growth retardation in Drosophila similar to that in human LMHD
Abstract Background Phosphatidylserine synthase (PSS), localized in the mitochondrial membrane, synthesizes phosphatidylserine. In humans, mutations in Pss lead to Lenz–Majewski hyperostotic dwarfism, a disorder affecting growth and development. The effects of Pss mutations on the growth of Drosophila melanogaster are not fully known. Hence, this study
Kwan‐Young Kim +4 more
wiley +1 more source
Aerosol sampling methods for the virus of foot-and-mouth disease and the measurement of virus penetration through aerosol filters [PDF]
H.V. Thorne, T. M. Burrows
openalex +1 more source
Epidemiology and economics of foot-and-mouth disease: current understanding and knowledge gaps. [PDF]
Humphreys JM +10 more
europepmc +1 more source
EMPower the heArt of patients with TermInal Cancer using Cardiac medicines (EMPATICC). eGFR, estomated glomerular filtration rate; EP, endpoint; FCM, ferric carboxymaltose; LVEF, left ventricular ejection fraction; N‐terminal pro‐B‐type natriuretic peptide; PGA, patient global assessment; PoC, proof of concept; QoL, quality of life; UICC, Union for ...
Markus S. Anker +23 more
wiley +1 more source

